Spot on mate. They are stuck in the usual biotech loop. They...

Spot on mate. They are stuck in the usual biotech loop. They need money to get data, and they need data to raise money. It’s a tough spot.

That’s why they got to start being smarter with how they run things. Right now they got three trials going — Azer-cel, Vaxinia, and onCARlytics. All three might have potential, but trying to run them all at once without the funding to support it properly is a big ask.

Might be time to shift more focus and funding toward the program with the best shot of delivering near-term results. They probably can’t just stop trials once they started, but they can scale back on how fast they are moving or how many sites they are running until they got the cash to support it properly. They also need to show a bit of discipline. Cut salaries, reduce spending, and send a clear message that they are making the hard calls, not just hoping for another raise.

Everyone wants the science to work, but they need to start acting like a company that knows cash is tight. Right now, investors are looking for more than hope. We all want to see a plan that actually makes sense!!!